Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.99

Chimerix, Inc. (NASDAQ:CMRX)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.99 and traded as low as $0.88. Chimerix shares last traded at $0.88, with a volume of 267,453 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Saturday, June 8th.

Chimerix Stock Down 1.5 %

The firm has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $0.99.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same period last year, the firm earned ($0.24) earnings per share. Equities research analysts expect that Chimerix, Inc. will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Chimerix

Hedge funds have recently modified their holdings of the stock. Pale Fire Capital SE raised its holdings in shares of Chimerix by 113.6% in the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 112,318 shares in the last quarter. Vestal Point Capital LP bought a new stake in Chimerix during the 4th quarter worth approximately $1,348,000. Assenagon Asset Management S.A. grew its position in Chimerix by 17.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 72,719 shares during the last quarter. Vance Wealth Inc. bought a new stake in Chimerix during the 4th quarter worth approximately $46,000. Finally, RA Capital Management L.P. bought a new stake in Chimerix during the 3rd quarter worth approximately $6,240,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.